Comparison of First-Line FOLFOX versus FOLFIRI in RAS Mutant Metastatic Colorectal Cancer Patients

Creative Commons License

Topal A., Akdağ G., Dumludağ A., Köseoğlu Ç., Kuzu Ö. F., Atacan H., ...Daha Fazla

Journal of Oncological Science, cilt.11, sa.2, ss.96-103, 2025 (Scopus, TRDizin)

Özet

Objective: Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality, with rat sarcoma (RAS) and proto-oncogene B-raf (BRAF) mutations associated with worse prognosis in metastatic settings. Despite advances in treatment, the optimal chemotherapy backbone combined with bevacizumab in RAS/BRAF-mutant metastatic CRC remains unclear. Our study aimed to investigate the best chemotherapy backbone in this patient group. Material and Methods: This retrospective study compared the efficacy and safety of first-line infused 5-fluorouracil, folinic acid and oxaliplatin (mFOLFOX6)+bevacizumab versus infused 5-fluorouracil, folinic acid and irinotecan (FOLFIRI)+bevacizumab in patients with RAS/BRAF-mutant metastatic CRC treated between November 2016 and January 2024. Overall survival (OS), progression-free survival, and clinical characteristics were evaluated. Statistical analyses included Kaplan-Meier survival estimates, Cox regression models, and subgroup analyses. Results: Among 130 patients, the median OS was significantly longer in the mFOLFOX6+bevacizumab group [22.6 months, 95% confidence interval (CI): 16.0-29.2] compared to the FOLFIRI+bevacizumab group (15.8 months, 95% CI: 10.7-20.8). ECOG performance status and chemotherapy backbone were significant prognostic factors for OS. Subgroup analysis revealed that patients with Eastern Cooperative Oncology Group performance status 2-4, and those with de novo metastases had worse outcomes, while younger patients (<60 years) benefited more from FOLFIRI+bevacizumab. Conclusion: mFOLFOX6+bevacizumab demonstrated superior survival outcomes compared to FOLFIRI+bevacizumab in first-line treatment of RAS/BRAF-mutant metastatic CRC. These findings highlight the need for further randomized, prospective trials to validate these results and inform treatment strategies for this challenging patient population.